- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic hypoparathyroidism
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Palopegteriparatide – July 2025
Palopegteriparatide; Solution for subcutaneous injection 168 micrograms in 0.56 mL pre-filled pen, Solution for subcutaneous injection 294 micrograms in 0.98 mL pre-filled pen, Solution for subcutaneous injection 420 micrograms in 1.4 mL pre-filled pen; Yorvipath®
Last updated
9 July 2025
